Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

Merck and Moderna’s personalised cancer vaccine shows promise in high-risk melanoma patients

The vaccine in combination with Keytruda reduced the risk of recurrence or death by 44%

- PMLiVE

Eli Lilly shares adjusted financial guidance for 2023

Lilly’s projection for revenue in the new year is set to be between $30.3bn and $30.8bn

- PMLiVE

Launching PMLiVE’s T40 – 2022 edition

A listing of the top 40 creative agencies working on advertising, branding, creative and design projects in the UK healthcare sector

- PMLiVE

Takeda to acquire Nimbus’ TYK2 inhibitor in deal worth $6bn

NDI-034858 is under evaluation for the treatment of multiple autoimmune diseases

- PMLiVE

Novartis partners with Cancer Research UK for rare cancer trial

The trial enrolled both paediatric and adult patients with any rare form of cancer

- PMLiVE

Addressing the diversity issue in clinical trials

How patient-centric analytics can be used to design more diverse, inclusive and equitable trials

Can Artificial Intelligence Solve the Healthcare Crisis?

Healthcare systems around the world are already struggling to meet the demands of an ageing population, the rising incidence of chronic diseases, escalating healthcare costs and a deficit of healthcare...

Page & Page Health

- PMLiVE

WHO publishes brief calling for integrated approach to epilepsy treatment

Epilepsy affects over 50 million people globally and accounts for 125,000 death per year

- PMLiVE

Amgen announces plans to acquire Horizon for $27.8bn in biggest pharma deal for 2022

The acquisition will see Amgen pay $116.50 for each Horizon share in cash

- PMLiVE

AbbVie receives extended SMC recommendation for Rinvoq in rheumatoid arthritis patients

In Scotland, there are around 44,000 people living with the progressive autoimmune disease

- PMLiVE

Janssen’s Imbruvica shows promise in chronic lymphocytic leukaemia study

The data was shared during the 2022 American Society of Hematology Annual Meeting

- PMLiVE

Roche shares phase 3 Polivy data for previously untreated diffuse large B-cell lymphoma

Results continue to show significant reduction in risk of death for DLBCL patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links